Welcome to our blog!

Parkinson's disease is not only the second most prevalent neurodegenerative disease after Alzheimer's disease, but also the fastest growing. With the number of cases steadily increasing, there is an urgent need for innovative therapeutic approaches. Scientists at the world-renowned Spaulding Rehabilitation...

Alzheimer’s disease (AD) continues to pose one of the greatest challenges in medicine, with progressive cognitive decline and limited treatment options. A recently published study by Cont et al., under the lead of Prof. Lars Wojtecki, explores the potential of Transcranial...

The newly released video publication on Transcranial Pulse Stimulation (TPS) for patients with Alzheimer’s disease by Cont et al., led by TPS expert and key opinion leader Prof. Lars Wojtecki, has recently been published by »Journal of Visualized Experiments (JoVE)« in the...

Alzheimer’s disease (AD) is clinically characterized by progressive cognitive decline, affecting memory, language, orientation, and behaviour. Neural oscillations, also known as brain waves, are integral to cognitive processes but become dysregulated in AD, contributing to network dysfunction and memory impairments. Targeting...

A new milestone in TPS research for Alzheimer’s has been achieved! For the first time, scientists have conducted a detailed animal study on healthy and transgenic mice with Alzheimer’s to explore the effects of Transcranial Pulse Stimulation (TPS). This study, a...

Alzheimer's disease is a challenging condition that affects millions of people worldwide. It gradually impairs memory, thinking, and other mental abilities, making everyday life difficult for those affected and their loved ones. While there are treatments that help manage the symptoms,...

Wondering how Transcranial Pulse Stimulation (TPS) could help treat Alzheimer’s disease? In this video, you will find an explanation of Prof. Lars Wojtecki’s study that investigates the safety and effectiveness of TPS, an innovative brain stimulation technique, for patients with mild...

Transcranial Pulse Stimulation (TPS) is an innovative treatment method for patients with Alzheimer's dementia. To better understand its application, obtain an overview of patient numbers and gain a clinical global impression of the treatment outcomes, we conduct annual surveys. In this...

Neurological disorders, encompassing a wide spectrum from neurodevelopmental conditions to late-life neurodegeneration, represent a significant global health challenge. The Global Burden of Disease Study 20211, published in The Lancet Neurology 2024, offers a comprehensive insight into the impact of 37 neurological...

Transcranial Pulse Stimulation (TPS) as a non-invasive brain stimulation method is now accessible in over 43 countries worldwide. The availability of TPS in a growing number of countries reflects its increasing relevance as an add-on treatment option for patients with Alzheimer’s...

A team from the Italian television station Business24 visited STORZ MEDICAL at its head office in Tägerwilen. The renowned TV presenter Anna Falchi interviewed STORZ MEDICAL employees Alessandro Saccucci, Head of »Office Line« Sales and Dr Dilana Hazer-Rau, Neurology Product Manager,...

On 18 November 2023, neurologists and psychiatrists from 14 countries met up at the second international TPS expert meeting in the German town of Konstanz (by Lake Constance) to discuss the use of Transcranial Pulse Stimulation as an additional therapy option...

Shock waves are acoustic pulse waves and allow physical energy to take effect in localised areas of tissue. In Neurology, we refer to the use of shock waves as Transcranial Pulse Stimulation (TPS). TPS is performed with the NEUROLITH® system and...

The first international expert meeting on Transcranial Pulse Stimulation (TPS) took place in Berlin on 29 April 2023. In the former Kaiserin-Augusta-Hospital, 30 neurologists and psychiatrists from 8 different countries met to discuss current TPS topics related to the treatment of...

STORZ MEDICAL participated in the »17th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) 2023« in Gothenburg, Sweden, from March 28th to April 1st, 2023 with the NEUROLITH system.

STORZ MEDICAL participated in the »5th International Brain Stimulation Conference (BrainSTIM)« in Lisbon, Portugal, from 19 – 22 February with the NEUROLITH®. In addition to live demonstrations at the STORZ MEDICAL booth, several exciting presentations were given by key opinion leaders...

Prof. Dr Ulrich Sprick (Head Physician of the Outpatient Centre at Alexius/Josef Hospital in Neuss, Germany) spoke in a live webinar organised by STORZ MEDICAL on the topic of »Transcranial Pulse Stimulation (TPS) – an innovative method for treating symptoms of...

Several studies by a research team at the Medical University of Vienna, Department of Neurology, have already shown that patients with symptoms of Alzheimer’s dementia report an increase in cognitive abilities (measured by CERAD test) after TPS and also report a...

Transcranial Pulse Stimulation (TPS) continues to be on the road to success: The 100th NEUROLITH® system was installed at the beginning of June 2022. The latest TPS location is the Lengg Clinic in Zurich, Switzerland. Dr. med. Bartosz Bujan (Medical Director...

»New hope for Alzheimer's patients: Patient's memory improves«*: On 22 April 2022, the front-page lead story of Germany's highest-circulation daily newspaper BILD (reach 7.62 million predominantly older readers) was about Transcranial Pulse Stimulation (TPS) with the NEUROLITH®.

Another study by Matt et al. (Medical University of Vienna, University Department of Neurology) published in February 2022 now presented a detailed sub-analysis of possible anti-depressive effects of Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system based on neuropsychological and functional imaging data.²

A study by Matt et al. (Medical University of Vienna, University Department of Neurology) published in January 2022 investigates the long-term effects of Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system on human brain and behaviour.¹ The randomised, sham-controlled and double-blinded study provides sham-controlled evidence for such effects for the first time.

In diesem hochinformativen Webinar sprechen unsere Key Speaker über wissenschaftliche Hintergründe und klinische Daten der Transkraniellen Pulsstimulation (TPS) bei Patienten mit Alzheimer-Demenz und teilen Praxiserfahrungen mit der Handhabung und den klinischen Auswirkungen. Anschliessend geht es in eine offene Diskussion mit einer Q&A Session über. Gerne können Sie uns Fragen rund um das Thema NEUROLITH® & TPS auch bereits im Vorfeld senden.

Transcranial Pulse Stimulation (TPS) celebrates its debut in Ukraine: The first NEUROLITH® system was installed in the western Ukrainian city and cultural centre of Lviv (approx. 750,000 inhabitants) on 12 January 2022. Now, Alzheimer's patients can receive treatment at »BRAINSPOT LVIV«, a clinic for neuromodulation (Director: Tomas Dzeminskyy, Chief Medical Officer: Andrii Hul). The first therapy sessions have already taken place.

In early January 2022, a study on the development of global dementia prevalence published by the medical journal The Lancet Public Health¹ received a lot of attention. The study predicts that the number of cases will triple to 152.8 million by 2050.The World Alzheimer Report 2019 already came to a similar assessment. The most important factors for this explosive development are the ageing of the global population and its further growth.

It's getting exciting: In the RTL News report »Neue Alzheimer-Therapie: Sanfte Stosswellen bringen Gedächtnis zurück«. Prof. Dr Musa Citak introduces in his practice in Hamburg the NEUROLITH® system and the treatment method, Transcranial Pulse Stimulation – short TPS.
TPS as a modern therapy method for the treatment of Alzheimer's dementia stimulates different brain regions even in deeper areas.

Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system is a new therapy option for patients with Alzheimer’s disease that allows targeted stimulation of cerebral regions.

Key-facts:

• TPS are shock waves which allow highly focal brain stimulation deep in the brain.
• TPS allows unprecedented precision for targeting brain areas.
  

Transcranial Pulse Stimulation (TPS) with the NEUROLITH® is increasingly gaining momentum: Since the CE approval for the »treatment of the central nervous system of patients with Alzheimer’s disease« in 2018, more than 50 NEUROLITH® systems have been installed worldwide. In June 2021, three more devices were installed in renowned neurological specialist clinics in Germany, Austria, and Turkey.

One of the highlights of the new NEUROLITH® system is its innovative BodyTrack software – a unique tool for the visualization and control of the TPS pulses applied and of treatment progress. Real-time tracking of the handpiece position enables automatic visualization of the treated regions. The use of personalized MRI data allows specific characteristics of the patient’s brain to be taken into account.

»Overall, I feel good after the treatment and progress has been made. I notice that I respond well when someone talks to me and find the words to express myself better. In addition, my memory has improved somewhat. When I go shopping, I take the shopping list just to be on the safe side, although I could do without it.

Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system is performed by a trained practitioner and is done on an outpatient basis. During treatment, the patient sits comfortably in a chair and can move freely at any time. To ensure optimal transmission of the pulses, the therapist applies ultrasound gel to the scalp or hair – it is not necessary to shave the patient’s head. The patient then puts on a pair of special glasses so that the position of the head can be detected.

The authors of a follow-up study (published in 2021) investigated the possible benefits of TPS treatment concerning brain morphology, namely the cortical atrophy characteristic of Alzheimer’s disease [1]. They found a significant correlation between neuropsychological improvement and cortical thickness increase in AD-critical brain areas.

»Laughing and being happy - for healthy people this is normal. During my TPS treatments, I notice that this is no longer normal for my patients. Many are sad and seem withdrawn. This is understandable when you can no longer do things the way you used to. I am all the more pleased when relatives call me after the first TPS treatments with the NEUROLITH® or write to me that their loved ones are now happier again and that they are smiling more often.

In 2019, the clinical approval study for Transcranial Pulse Stimulation (TPS) with STORZ MEDICAL’s NEUROLITH® system was published in the prestigious journal Advanced Science [1]. Prof. Dr. Beisteiner’s study, which was conducted at the Medical University of Vienna Beisteiner, documents the positive effects of TPS in the treatment of patients with Alzheimer’s dementia.

Note: The following article and the film shown are in German.

Im Film »Wie hilft Ultraschall gegen Alzheimer« wird spannend unsere Transkranielle Pulsstimulation (TPS) vorgestellt.

Also das moderne Therapieverfahren zur Behandlung von Alzheimer-Demenz durch die Stimulation verschiedener Gehirnregionen.

The acoustic pulses generated by Transcranial Pulse Stimulation (TPS) have been used successfully in various medical fields (urology, orthopaedics, cardiology….) for decades under the term »extracorporeal shock wave therapy«.

Shock waves are similar to ultrasound. But there is a major difference:

In 2018, Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system was the first, and hitherto only, procedure of its kind to obtain market authorization for the »treatment of the central nervous system of patients with Alzheimer’s disease«. The aim of TPS is to boost the cognitive abilities of people with Alzheimer’s dementia by stimulating various regions of the brain and to maintain these abilities for as long as possible.